Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells

Yuhao Shi¹, Melissa Dolan¹, Michalis Mastroi², James W. Hill³, Adam Dommer²,
Sebastien Benzekry⁴, Kevin Eng^{2,5}, and John M.L. Ebo^{1,2,6}

- 1 Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263. USA
- 2 Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263. USA
- 3 Jacobs School of Medicine and Biomedical Sciences, SUNY at Buffalo
- 4 COMPutational pharmacology and clinical Oncology, Inria Sophia – Antipolis, Centre de Recherches en Cancérologie de Marseille, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Faculté de Pharmacie, Aix-Marseille University
- 5 Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263. USA
- 6 Department of Medicine, Roswell Park Comprehensive Cancer Center Buffalo, NY, 14263. USA

* Correspondence: John M.L. Ebo, Roswell Park Comprehensive Cancer Center, Center for Genetics and Pharmacology, Elm and Carlton Streets, Buffalo, NY 14263-0001. Phone: 716-845-8233; Fax: 716-845-8232; E-mail: John.Ebo@RoswellPark.org

Abstract

Therapeutic inhibition of programmed cell death ligand (PD-L1) can reverse PD-1-mediated suppression of tumor-killing T-cells; however, many patients develop resistance. Acquired resistance may be derived from intracellular PD-L1 and interferon (IFN) signaling programs in the tumor that can have dual, sometimes opposing, influences on tumor immune responses. Here we show that PD-L1 inhibition induces a novel secretory program tightly controlled by IFN-signaling and specific to acquired, but not innate, resistance in tumors. A PD-L1 treatment-induced secretome (PTIS) was found to be enriched for several IFN-stimulated genes (ISGs) and then further enhanced by type I IFN stimulation (IFN α or IFN β) in multiple mouse tumor models. Chronic inhibition or gene knockout of tumor PD-L1 *in vitro* could elicit similar type I IFN-enhanced secretory stimulation while resistant cells were able to suppress T cell activation and killing *ex vivo*. When reimplanted into mice, resistant tumors were more sensitive to IL-6 inhibition (a key PTIS component) and growth significantly reduced when type I IFN signaling was blocked. Together, these results show that prolonged PD-L1 inhibition can ‘rewire’ existing intracellular IFN:PD-L1 signaling crosstalk to drive secretory programs that help protect tumors from immune cell attack and represent a targetable vulnerability to overcome acquired resistance in patients.

Introduction

Cancer therapies can provoke unexpected (and often unwanted) cellular reactions that include the secretion of proteins such as growth factors and cytokines – many of which have been exploited as possible biomarkers of treatment effect or toxicity in patients¹⁻³. Such therapy-induced secretomes (TIS) can also contribute to cancer progression, particularly in settings of acquired resistance where tumor cell populations adapt to treatments over prolonged periods³. For immune-checkpoint inhibitors (ICIs) that target the programmed cell death 1 (PD-1) pathway, early cytokine changes (e.g. IL6, IL8) in patients after treatment can correlate with initial responses^{4,5} or adverse events⁶, but whether tumor-specific secretory profile changes can be a cause (or consequence) of acquired resistance remains unclear^{3,7}. This may be because blockade of programmed death ligand 1 (PD-L1) expressed on tumor cells is typically thought to inhibit growth primarily via tumor-*extrinsic* functions, namely, by restoring the cell-killing functions of cytotoxic T cells controlled by PD-1 signaling^{8,9}. It is perhaps less appreciated that tumor-*intrinsic* intracellular functions of PD-L1 can also help tumors evade immune detection⁸. Indeed, PD-L1 has signaling crosstalk with multiple processes such as mTOR/AKT^{10,11}, MAPK¹², STAT3/Caspase 7¹³, integrin β ¹⁴, MerTK¹⁵, BIM/BIK¹⁶ – all of which can protect tumor cells from T cell-mediated cytotoxicity¹⁷ (see¹⁸ for review).

In this regard, the effect of interferons (IFNs) on tumoral control of secretory programs following acquired resistance to PD-L1 inhibition may be of interest for several reasons^{3,19}. First, Gato-Canas and colleagues recently showed that PD-L1 can signal via three conserved intracellular motifs and exert direct regulatory control of IFN-mediated cytotoxicity through inhibition of STAT3/Caspase7¹³. Second, IFNs have been linked to multiple ICI treatment resistance mechanisms mostly via the induction of IFN-stimulated genes (ISGs) activated by type

I (α/β) and type II (γ) IFN subtypes. Currently the precise effect of IFNs on PD-L1 inhibitor efficacy remains enigmatic because they can, somewhat paradoxically, both protect and weaken immune defenses (often simultaneously)^{20,21}. For instance, IFNs can boost antigen presentation (e.g. via beta-2-microglobulin and MHC-I expression) to improve PD-1 inhibitor responses^{22,23}, while also suppressing immune cell attack via the induction of T-cell inhibitory ligands^{20,24}, NOS2²⁵, and SerpinB9²⁶, amongst many others^{27,28}. Finally, IFNs also can regulate a range of cellular processes that involve additional cytokine production^{29,30} that, in turn, can have positive and negative effects on tumor progression. Currently it is unknown whether these IFN-controlled secretory programs are enhanced (or inhibited) in tumor cells in the context of acquired resistance, where persistent PD-L1 blockade may impact immune-protective processes.

Here we used treatment-sensitive mouse models to generate PD-L1 drug resistant (PDR) tumor cells to evaluate changes in secretory profiles. Using transcriptomic and proteomic analysis, we identified a PD-L1 treatment-induced secretome (PTIS) signature that was enriched for ISGs and could be validated in multiple datasets involving PD-L1 therapy. Type I IFN β stimulation was found to potently enhance PTIS expression, even in tumor cells chronically exposed to drug *in vitro*, suggesting direct drug actions can alter secretory machinery controlled by PD-L1:IFN signaling crosstalk. PDR cells were also found to have enhanced immune protection from CD8+ T cell cytotoxicity and blockade of specific PTIS ISGs (such as IL-6) or IFN receptor that enhanced anti-tumor effects. Together, these results show that tumor-intrinsic immune protective secretory changes occur following acquired resistance to PD-L1 inhibition and identify a novel rationale for targeting type I IFNs to improve patient outcomes after treatment failure.

Results

Acquired resistance to PD-L1 inhibition increases secretory profiles enriched for type I IFN regulated genes

To examine acquired resistance to PD-L1 inhibition, the PD-1 pathway inhibitor-*sensitive* murine breast tumor EMT6 cell line ³¹⁻³³ was implanted orthotopically in Balb/C mice and treated with α PD-L1 (clone 80) or IgG control antibody (**Fig 1a; schematic shown**). Following continuous treatment, a PD-L1 drug-resistant (PDR) cell variant (EMT6-PDR) was selected from mice with tumors that resumed growth after an initial significant delay (**Fig 1b; circles shown**). Transcriptome RNA-sequencing of EMT6-PDR and EMT-P (parental) tumor tissues revealed multiple genes to be up- or down-regulated (**Fig 1c**). Gene-set enrichment analysis (GSEA) showed EMT6-PDR tumors to be significantly enriched for genes associated with extracellular matrix, growth factor, and cytokine signaling pathways, several of which were secreted and IFN-regulated (**Fig 1d**). Using the Gene Ontology (GO) database term GO:0005576 consisting of products outside or unattached to the cell ¹⁹, secretory genes were found to increase in EMT6-PDR tumor transcripts and associate with inflammatory signaling, wound healing, and immune cell function/migration (**Fig 1e**). Since many of these processes also associate with IFN signaling ^{30,34}, we examined IFN-regulated genes using the Interferome database - a compilation of published *in vitro* and *in vivo* experimental datasets identifying transcriptomic and proteomic changes after IFN treatment ³⁵. Compared to P controls, EMT6-PDR tumors had several IFN-related genes up- and down-regulated (54% and 63%, respectively), with type I IFN gene upregulation the most common (22% of total) (**Fig 1f**). Several IFN stimulated genes (ISGs) and type I IFNs were confirmed to be upregulated in EMT6-PDR cells using qRT-PCR analysis (**Fig 1g**). Next, we tested whether IFN gene enrichment could also be detected in tumors innately resistant to α PD-L1 treatment. To

do this, we first implanted the PD-1 pathway inhibitor-*insensitive* murine kidney tumor RENCA cell line orthotopically into Balb/C mice³⁶ and, following treatment with α PD-L1 or IgG antibody (**Fig 1h; schematic shown**), selected a RENCA-PDR tumor cell variant that did not respond to treatment (**Fig 1i; circles shown**). EMT6-PDR and RENCA-PDR cells were then compared for relative enrichment of IFN signaling gene-sets found in several publications^{20,21,37-39} and in the Hallmark Molecular Signatures Database (MSigDB)⁴⁰ (**Table S1**), with only EMT6-PDR cells showing positive enrichment (**Fig 1j; RENCA-PDR negatively enriched**). Next, a similar comparison was performed using an IFN γ -associated gene-set identified in durvolumab-treated non-small cell lung carcinoma (NSCLC) patient tumor biopsies⁴¹, with only EMT6-PDR cells showing positive enrichment (**Fig 1k**). Taken together, these results demonstrate that α PD-L1 treatment can induce ISG-related secretory gene changes in tumors that may be specific to acquired, but not innate, resistance settings.

A PD-L1 treatment-induced secretome (PTIS) is enriched in PD-L1 treatment-sensitive clinical and preclinical models

To examine this further, we next tested whether IFN-enriched secretory effects found after acquired resistance were unique to tumor models reported to be initially sensitive to PD-L1 treatment. To do this, we developed a composite of secretory genes and proteins found to be increased in EMT6-PDR tumors based on RNAseq, qRT-PCR, cytokine array, and ELISA analysis (**Fig S1; see Methods**). From this, we identified a α PD-L1 treatment-induced secretome (PTIS) signature consisting of 13 up-regulated molecules, with 12/13 representing IFN-regulated genes identified via the Interferome Database (**Fig 2a**). We next tested for PTIS signature enrichment in publicly available NCBI GEO and dbGAP whole transcriptome datasets from published preclinical

and clinical studies involving α PD-L1 treated tumors. In 5 preclinical studies examined, 3 were reported as α PD-L1 treatment-*sensitive* (Lan et al.³¹; Sceneay et al.⁴²; Efremova et al.⁴³) and 2 were α PD-L1 treatment-*insensitive* (Sceneay et al.⁴² and RENCA-PDR tumor cells from this study) (**See Methods for details**). PTIS signature expression was found to increase in all α PD-L1 treatment-*sensitive* models as defined by average counts per million (CPM) levels, with 2 of 3 models demonstrating significant positive GSEA enrichment and 1 of 3 models showing significance by both CPM expression and GSEA enrichment (**Fig 2b**). Conversely, PTIS signature expression was decreased in α PD-L1 treatment-*insensitive* models (**Fig 2c**). In 2 clinical studies examined, tumor biopsies were taken from non-small cell lung carcinoma (NSCLC) (Gettinger et al.⁴⁴) and merkel cell carcinoma (MCC) (Paulson et al.⁴⁵) patients reported to be initially sensitive to α PD-L1 treatment (**See Methods**). In the NSCLC study, the PTIS signature expression was increased and significant positive GSEA enrichment found in bulk RNAseq data from patients who developed acquired resistance (**Fig 2d**). In MCC, single-cell RNAseq datasets also had increased PTIS signature expression in tumor, macrophage, and T-cell enriched cell compartments after clustered analysis (**Fig 2e**; **See Methods**). Notably, we generated a separate PTIS using only genes *downregulated* in EMT6-PDR cells (termed 'PTIS^{DOWN}'); however, similar dataset validations were not consistent suggesting the *upregulated* PTIS is more representative of acquired resistance (**Fig S2a**; **See Supplemental Results**). Together, these findings demonstrate that the IFN-enriched PTIS is increased in multiple preclinical and clinical tumors initially *sensitive* to α PD-L1 treatment, and occurs independent of cancer type.

Type I IFN stimulation enhances PTIS expression in PDR cells

Since many ISGs found in the PTIS can be regulated by type I IFNs (α , β) binding to IFN alpha receptor (IFNAR)⁴⁶, we next examined whether IFN stimulation could impact PTIS after acquired resistance. To test this, EMT6-P and PDR cells were incubated with recombinant type I IFNs (α or β) or type II IFN (γ) for 48 hours (10ng/ml). Multiple ISGs (*IL6*, *Nos2*, *Cxcl9*, *Rsad2*) found to be upregulated in EMT6-PDR cells were further enhanced by IFN stimulation (**Fig 3a; exception *Cxcl9***). Notably, of the PTIS factors tested, *IL6* expression increases were the most robust in EMT6-PDR cells before and after type I IFN stimulation (**Fig 3b; heatmap summarizing relative expression shown**). This stimulatory effect was confirmed in protein studies using conditioned media (CM), where IFN β was found to be the strongest inducer of IL6 after resistance (**Fig 3c**). Notably, anti-proliferative effects of IFN treatment⁴⁷ were not found to be consistently different amongst EMT6-P and PDR cells (**Fig S3**). To further examine whether IFN-enhanced PTIS is primarily regulated by type I IFN signaling, IFNAR1 was knocked down in EMT6-P and PDR cells (designated IFNAR1^{KD}) via short hairpin RNA (**Fig 3d**). Results showed that increases in IL6 expression by IFN β -stimulation could be reversed in EMT6-PDR-IFNAR1^{KD} cells (**Fig 3e**). Finally, since tumoral PD-L1 intrinsic functions and expression have been reported to regulate and be regulated by IFN signaling (particularly via STAT phosphorylation)^{13,48}, PD-L1 levels and STAT activation were examined after acquired PD-L1 treatment resistance and after IFN β stimulation. First, PD-L1 was found to be significantly decreased in EMT6-PDR variants compared to P controls, and were found to remain decreased after i) IFN β -induced expression elevations, and ii) IFNAR1 knockdown (**Fig 3f**). Second, total STAT1 expression was also found to decrease expression in EMT6-PDR cells compared to P controls while total STAT3 levels remained unchanged (**Fig 3g; blotting replicates in Appendix 1; densitometry to β -actin shown in Fig 3h**). Despite this expression decrease, IFN β treatment led to a significant increase in

pSTAT1 and pSTAT3 (relative to total protein levels) in EMT6-PDR cells compared to P controls, an effect that was partially reversed in PDR-IFNAR1^{KD} cells (**Fig 3i**). As confirmation, pSTAT3 levels were also examined via ELISA assays which yielded similar findings (**Fig 3j**). Taken together, these results show that increased PTIS expression after acquired resistance can be further enhanced by IFN stimulation - particularly IFN β - and regulated primarily via type I IFN-controlled intracellular signaling in tumor cells.

Persistent PD-L1 blockade *in vitro* sensitizes tumor cells to type I IFN stimulation of PTIS

To examine whether IFN-regulated PTIS effects after acquired resistance could be directly linked to inhibition of PD-L1 on tumor cells, EMT6 cells were chronically treated with α PD-L1 (clone 80) or IgG *in vitro* for >4 weeks to generate EMT6-P^{VITRO} and PDR^{VITRO} cell variants (**Fig 4a; schematic shown**). Global transcriptomic changes found using RNAseq analysis revealed multiple genes to be up- or down-regulated (**Fig 4b**). While these gene changes were comparatively less robust than in *in vivo*-derived EMT6-P and PDR tumor tissue (**Fig 4c**) and found not to consistently differ between individual ISGs (data not shown), the PTIS signature was significantly enriched in EMT6-PDR^{VITRO} cells compared to parental controls (**Fig 4d**). EMT6-PDR^{VITRO} cell variants were also found to be enriched for several IFN-associated gene sets from published datasets (**Fig 4e**) and in tumor tissues taken from durvalumab-treated NSCLC patients (**Fig 4f; See Methods and Table S1**). Critically, multiple ISGs of the PTIS (including IL6) were found to be significantly enhanced in EMT6-PDR^{VITRO} cells following IFN β stimulation compared to parental controls (**Fig 4g: 4h shows heatmap summary**), indicating that type I IFN-controlled secretory changes in the tumor can be, at least in part, a direct response to PD-L1 inhibition. For confirmation, we next tested whether similar results could be obtained using different cancer cell

types and different PD-L1 inhibition strategies. First, using a α PD-L1 antibody (MIH5), we generated a mouse colorectal CT26-PDR^{VITRO} cell line and found IL6 protein expression to significantly increase before and after IFN β -stimulation (**Fig 4i**). Second, using a PD-L1 knock-out B16 mouse melanoma tumor cell line (B16^{PDL1-KO}; described previously ¹³), we found IFN β stimulation could also increase multiple ISGs (**Fig 4j; 4k shows heatmap summary**). Detailed analysis of IL6 in B16 was limited by low gene and protein expression levels (data not shown), though it is notable that similar trends were observed. Finally, to determine whether type I IFN-enhanced PTIS changes are specific to the duration of treatment, we compared EMT6 cells exposed to α PD-L1 (clone 80) for long- (> 4 week) and short-term (1 week) periods. Results showed IFN β -stimulated IL6 expression to be significantly increased after longer, but not shorter, duration (**Fig 4l**). Taken together, these results show that persistent PD-L1 blockade can lead to tumor-specific adaptations involving intracellular PD-L1:IFN signaling that, in turn, can sensitize tumor cells to enhanced type I IFN-driven secretory changes.

PDR-mediated immune-protection is IFN signaling-dependent

Next, we assessed whether the cellular and secretory changes in PDR cells might influence (or be influenced by) immune cell populations typically part of the anti-tumor response. We first performed CIBERSORT/ImmuCC tissue deconvolution analysis to identify mouse gene scores representing immune cell populations in RNAseq data from EMT6-P and -PDR tumors (described in ^{49,50}). EMT6-PDR tumors had higher total immune scores (**Fig 5a**), with activated cytotoxic CD8⁺ T lymphocyte (CTL) and M2 macrophage scores significantly decreased (**Fig 5b**), indicating that anti-tumor immune response may be suppressed after resistance. Since a decrease in major histocompatibility complex class I (MHC-I) expression can help tumors evade cytotoxic

CD8⁺ T lymphocytes (CTLs) and can be impacted by IFN-signaling⁵¹, MHC-I was examined by flow cytometry (**Fig 5c;upper panel**) and found to be significantly decreased in EMT6-PDR (**Fig 5c;lower left panel**), with this decrease reversed in EMT6-PDR-IFNAR1^{KD} cells (**Fig 5c;lower right panel**). Next, we tested whether secretory factors released from resistant cells may influence CTL proliferation and activation markers. To do this, conditioned media (CM) from EMT6-P/PDR cells was incubated with dissociated mouse splenocytes containing CD8⁺ T cells activated by α CD3 and α CD28 antibodies (**Fig 5d; schematic shown**). Significant decreases in CD8 T-cell proliferation were found to be induced by EMT6-PDR CM (**Fig 5e**), something that was reversed in CM from EMT6-PDR-IFNAR1^{KD} cells (**Fig 5f**). Next, CM from EMT6-PDR cells was found to decrease CD8⁺ T cells co-expressing markers for cytotoxicity such as Granzyme B and IFN γ (both T-cell effector proteins capable of cell-killing^{52,53}) and CD69, an early T-cell activation marker⁵⁴, compared to unstimulated splenocytes and P controls (**Fig 5g**). This immune-suppressive effect was again found to be reversed in CM from EMT6-PDR-IFNAR1^{KD} cells (**Fig 5h**). Next, we tested for tumor cell cytotoxicity in response following co-culture with activated CD8⁺ T-cells (**Fig 5i; schematic shown**) using flow cytometry (**Fig 5j; representative images shown**). Results show that tumor markers for apoptosis (annexin V) and cell death (7-AAD) were significantly decreased in EMT6-PDR cells compared to P controls (**Fig 5k**), with this effect reversed in EMT6-PDR-IFNAR1^{KD} cells and apoptosis increased (**Fig 5l**). In the same co-culture studies, CTLs were also measured by flow cytometry; however, consistent results were not observed which we attribute to complex direct tumor:splenocyte interactions that may influence the outcome (**Fig S4a-e; See supplemental Results**). Together, these results identify two significant ‘immune protective’ changes to the tumor that occur after acquired resistance to PD-L1 inhibition. First, resistant cell secretory changes can suppress CD8⁺ T cell activation; and

second, tumoral IFN-signaling is ‘rewired’ to limit antigen presentation and response to anti-apoptotic stimuli.

Inhibition of PTIS regulators selectively inhibits PDR tumor growth

To examine whether immune-protective changes after acquired resistance to α PD-L1 inhibition can impact tumor growth *in vivo*, we first tested blocking individual PTIS molecules such as IL-6. In addition to IL-6 representing a PTIS protein consistently shown to be enhanced by IFNs in our PDR models, IL6 has also been shown to be a suppressor of anti-tumor immune responses and can improve PD-1 pathway inhibitor efficacy when targeted clinically and preclinically ^{4,55}. Following orthotopic implantation of EMT6-P and PDR cells, Balb/c mice treated with anti-mouse IL-6 (α -mIL-6) antibody showed a significant reductions in tumor growth only in the PDR variants, and not in the P tumor controls (**Fig 6a-right, daily growth and area under the curve (AUC) analysis; 6a-left, treated vs untreated comparison**). Next we tested whether blocking type I IFN-signaling control of the PTIS may have a more expanded impact on tumor growth after resistance, we implanted EMT6-P- and -PDR-IFNAR1^{KD} variants orthotopically into Balb/c mice (**Fig 6b-right, daily growth and AUC analysis; 6b-left, treated vs untreated comparison**). Notably, IFNAR1 knock-down in EMT6-P cells significantly increased tumor growth compared to P controls (**Fig 6b-blue lines**), providing confirmation of previous reports indicating that treatment-naïve tumor growth can be enhanced after type I IFN signaling blockade ^{56,57}. Conversely, growth of EMT6-PDR-IFNAR1^{KD} variants were found to be significantly inhibited compared to EMT6-PDR tumors, demonstrating that type I IFN-enhanced PTIS confers a ‘protective’ effect that, when inhibited, has strong anti-tumor effects specific to α PD-L1 resistant cells (**Fig 6b: red lines**). AUC analysis of results in 6A-B confirmed the magnitude of IL6 and

IFNAR1 inhibitory effect on EMT6-PDR tumors (**Fig 6c**). Interestingly, these PDR cell-specific effects may extend to inhibition of metastatic spread as post-mortem analysis at endpoint (Day 27 for α IL6, Day 26 for IFNAR1^{KD}) showed enhanced inhibition of tumor skin/abdominal wall invasion after α -mIL-6 (2.5-fold decrease in PDR vs 2-fold decrease in P tumors) and IFNAR1^{KD} (no invasion in PDR and 3.125-fold increase in P tumors) (**Fig 6d**). Taken together these results indicate that inhibition of PTIS and key regulators of its expression may provide enhanced benefit after acquired resistance to PD-L1 blockade.

Discussion

A subset of cancer patients who are initially responsive to PD-L1 inhibitors will develop acquired resistance^{58,59}. Mechanisms to explain why immunologically ‘hot’ tumors turn ‘cold’ remain complex as the microenvironment can adapt to treatment by relying on alternative checkpoints, inducing permanent T cell exhaustion, and recruiting/expanding an array of immunosuppressive cells – amongst many other changes attributed to host cell populations (reviewed in ref ^{58,60}). But there is increasing evidence that the tumor also adapts to PD-L1 blockade^{61,62}. Here, we examined the consequences of prolonged PD-L1 inhibition *in vivo* and *in vitro* on tumor cells and identified a unique PTIS signature that was associated with acquired resistance, enriched for numerous ISGs, and tightly regulated by type I IFN signaling. These tumor intrinsic adaptations were found to protect tumor cells from immune mediated cytotoxicity *directly*, via decreased sensitivity to lymphocytic attack, and *indirectly*, via a suppression of T cell activation by the PTIS. Importantly, resistant tumors were found to be uniquely vulnerable to IFN signaling disruption which, when targeted *in vivo*, could reverse immune-protective effects and enhance tumor growth inhibition. Together, these findings suggest that a consequence of chronic PD-L1 blockade includes a tumor intrinsic secretory signature that may serve as a biomarker and molecular driver of acquired resistance in patients.

Studies examining the basic mechanisms of ICI-mediated tumor inhibition have mainly focused on the effects of blocking PD-L1 extrinsic functions that modulate immune cells such as T-, NK-, and myeloid cell populations, amongst several others⁶³⁻⁶⁵. Yet tumor intrinsic PD-L1 signaling is also impacted by therapeutic inhibition and can contribute to resistance. For instance, PD-L1 has been described as a ‘molecular shield’ as it can protect tumor cells from T cell cytotoxicity induced by various treatments^{17,66} and by IFNs^{13,67}. Indeed, Gato-Canas and

colleagues found that type I IFN-induced cytotoxicity can be controlled by conserved motifs of PD-L1 cytoplasmic domains (RMLDVEKC and DTSSK), which block STAT3/Caspase 7 cleavage¹³. Our results show prolonged PD-L1 blockade can add to this immune-protective effect by altering IFN:PDL1 intracellular crosstalk which, in turn, can drive an IFN-enriched secretory program that contributes to treatment resistance. Indeed, we found PDR cells were less susceptible to activated splenocyte mediated cytotoxicity, had increased activation of STAT3/1-controlled anti-apoptotic programs after IFN stimulation⁶⁸, and had a secretory profile enriched for immunosuppressing factors such as SERPINB9, which serve as an endogenous inhibitor of granzyme B^{26,69}. This latter finding may explain why conditioned media from PDR cells was able suppress several markers of T cell activation and raises the question of whether inhibition of one protective mechanism (PD-L1) may be compensated for by other protective mechanisms (i.e., other ISGs). Such considerations may depend on several variables known to affect efficacy, including antibody type⁷⁰, treatment dose¹³, and treatment duration. On this latter topic, our results show that the IFN-enhanced PTIS could be replicated, at least in part, by direct antibody inhibition or PD-L1 knockout *in vitro*, but only after sustained inhibition periods longer than 1 month. This may be relevant to patients who develop acquired resistance to PD-L1 inhibition and receive treatment for up to two years, depending on trial protocols and tumor response^{44,71}. Because patient sub-sets have been shown to have highly durable responses to PD-1 pathway inhibition even after treatment discontinuation^{72,73}, our results may support rationale to avoid “over-treatment” with ICI^{74,75}.

An important implication for these studies involves the potential use of PTIS as a biomarker of acquired PD-L1 treatment resistance. Transcriptomic analysis comparing tumor tissues has shown ISGs can increase in both tumor and non-tumor cell populations before and after

ICI treatment in patients^{27,41,43,76}. Here we examined 5 preclinical and 3 clinical datasets and found the PTIS to be enriched in tumors initially sensitive to α PD-L1 treatment. This would suggest that assessing the PTIS signature in patient biopsies after treatment may have utility as a predictor for sensitivity levels, particularly given our results showing significant downregulation of PTIS in models of innate resistance. This may be feasible to test in tissues obtained after neoadjuvant PD-L1 inhibition such as in a current trial involving cutaneous melanoma patients treated with atezolizumab for 6 weeks (NCT04020809). It is also possible that monitoring individual PTIS factors might have predictive value in patients after treatment, though this is likely to be complex owing to the many functions of several proteins. For instance, secreted circulating factors such as IL6, CXCL9, and CXCL10 have been found to increase in patients after PD-1 pathway inhibition and correlate with tumor stabilization/shrinkage, as measured by objective response rates (ORR)^{6,77-79}. But few studies have yet to assess cytokine changes in patients after prolonged treatment durations that assess progression-free and overall survival (PFS/OS) outcomes^{7,80}. Results from such studies may be mixed as IL-6 at baseline can correlate with improved initial response to nivolumab in a phase II trial for advanced melanoma (measured by ORR)⁷⁷, but also predict for worse long-term outcome to PD-1/L1 inhibitors in NSCLC (measured by PFS)⁸¹. Furthermore, expression of some PTIS factors have been linked to both tumor-promoting and tumor-inhibiting immune responses depending on context. An example includes CXCL9 and CXCL10, which we found to be increased in IFN β -stimulated PDR cells; and thus far, been primarily associated with anti-tumor immune responses, including trafficking of cytotoxic T cells⁸²⁻⁸⁴. But in different disease types and tumor models, these cytokines can also be associated with recruitment of immune suppressive/tumor promoting T-regulatory cells⁸⁵⁻⁸⁷. In this regard, it is of particular interest that the PTIS was found to be enriched in non-tumor populations such as macrophages and

T cells of merkel cell carcinoma patients treated with avelumab (Fig 2E) - suggesting PD-L1 inhibition can likely induce ‘off-target’ host effects¹⁹. This may portend to the PTIS playing a role in immune related adverse events (irAEs) known to be induced by various ICI treatments and associated with the systemic increase in cytokines, such as IL6, IL1-RA, and CXCL10⁸⁸. Indeed, PD-1 targeting agents have been known to induce cytokine release syndrome, which is an adverse effect characterized by fever, myalgias, malaise, and high levels of cytokines including IL6 and IFNs^{89,90}. Assessment of the PTIS as a potential cause or consequence of these processes requires further investigation.

The impact of IFN signaling on tumor growth and overall efficacy of ICIs can have opposing, and often contradictory, effects depending on several factors that include the type of cell, the duration of IFN exposure, and the stage of tumor progression. Indeed, IFNs have been shown to have both stimulatory and inhibitory effects on tumor growth that can influence response to ICI treatment. For *inhibitory* effects, IFNs (mostly IFN γ) are integral to anti-tumor immunity by driving antigen presentation⁴⁴ and chemokine secretion⁹¹ that are typically part of the immune-editing process in normal physiological conditions. IFNs may improve ICI responses as loss of function mutations in IFN signaling components (JAK1/2) have been noted in melanoma patients who have relapsed after pembrolizumab treatment⁹², and knockout of IFN pathway mediators such as Jak1, Stat1, Ifngr1 in tumors can weaken ICI treatment efficacy^{93,94}. For IFN tumor *stimulatory* effects, Benci and colleagues demonstrated that ICIs can induce an enhanced expression of tumor cell ISGs transcribing additional T-cell co-inhibitory ligands (e.g. TNFRSF14, LGALS9) where blockade of type I and II IFN signaling could reverse this effect and improve ICI responses²⁰. Additional tumor ISGs regulated by type I IFNs such as NOS2²⁵ and CD38²⁷ can also have immune-suppressive effects and mediate acquired resistance to PD-1 pathway blockade.

Furthermore, high levels of type II IFN induced by combined PD-1/CTLA-4 blockade can also mediate deletion of anti-tumor T cells under low-tumor burden settings⁹⁵.

Due to these opposing roles for IFN, one question is whether negative consequences of IFN can be specifically targeted, without negating the positive IFN signaling effects. In this regard, Benci and colleagues proposed that ISGs promoting ICI resistance may be more associated with tumor cell expression²¹ and after chronic exposure to IFNs²⁰, compared to the largely positive effects of IFNs on immune cells and after acute IFN exposure. In these studies, sequential treatment of an ICI followed by a JAK inhibitor was found to sensitize IFN-driven resistant tumors to ICI treatment²⁰. Such treatment strategies are now being tested in clinical trials (NCT03425006). A second ISG targeting approach aims to block the individual ISG itself which, theoretically, could avoid suppressing IFNs anti-tumor functions. In our study, both approaches were evaluated. In the first, IFNAR1 knockdown in PDR cells was found to effectively reverse IFN β -mediated PTIS factor increases and reverse direct (and indirect) immune suppressive effects in co-culture studies with mouse splenocytes. This may explain why PDR-IFNAR1^{KD} tumors were found to grow slower than PDR tumors *in vivo*, and highlight the unique vulnerability induced by constant PD-L1 blockade. However, our results also show that IFNAR1^{KD} tumors grew much faster than parental controls, emphasizing the sometimes contradictory role of IFNAR signaling in cancer controlling immunosurveillance²⁸ may be exacerbated by PD-L1 treatment and, as a consequence, introduce potential challenges of intracellular IFN signaling inhibition strategies. In our second approach, we targeted IL-6, which is a specific component of the PTIS that was consistently increased in PDR cells and then further enhanced after IFN β stimulation. IL6 is known to activate a multitude of tumor promoting effects including (i) enhancing expression of pro-angiogenic factors in tumors cells (e.g. VEGF, IL1 β , IL8⁹⁶), (ii) suppressing antigen presentation from

dendritic cells⁹⁷, (iii) promoting pro-tumorigenic macrophage phenotypes⁹⁸, (iv) suppressing anti-tumor functions of CD4+ T cells⁹⁹, amongst others¹⁰⁰. Trials are currently underway testing IL6 and PD-1 pathway inhibitor combinations for improved anti-tumor efficacy and irAEs (NCT03999749, NCT04258150)^{101,102}. Our results show that IL6 inhibition can lead to enhanced growth suppression in PDR tumors supporting a rationale for IL6:PD-L1 combination/sequencing strategies. However, it should be noted that these effects were largely modest, suggesting targeting multiple PTIS factors simultaneously may yield more robust outcomes. In favor of this, preclinical models involving inhibition of CCL2¹⁰³, CCL5¹⁰⁴, NOS2²⁵, and SERPINB9²⁶ pathways have all shown benefits when combined with various ICIs and may be explored to improve IL6 inhibitory strategies after PD-L1 treatment failure.

Taken together, our results show that tumor cells following acquired resistance to PD-L1 blockade can express an ISG enriched secretory profile associated with diminished sensitivity to immune cell cytotoxicity. Therapeutic approaches involving inhibition of PTIS components or IFN regulators may have enhanced benefit after resistance to PD-L1 inhibition.

Acknowledgements

We would like to thank A. Haninec for helpful comments; and A. Tracz, S. Grant, A. June for their technical support. Select cell lines used in this study were kind gifts from various laboratories. These include EMT6 (A. Gukov) and B16 (D. Escors). We thank M. Azuma for providing MIH5 hybridoma for antibody production (see Methods) and M. Oberst at AstraZeneca for providing the Clone 80 antibody.

Funding: This work used shared resources supported by the Roswell Park Comprehensive Cancer Center (RPCCC) Support Grant from the National Cancer Institute (NCI) (P30CA016056). This work was supported by grants to JMLE from the American Cancer Society (ACS) via a Research Scholar Grant (RSG-18-064-01-TBG) and Roswell Park Alliance Foundation (RPAF); and to YS from NCI F30 CA243281. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the RPAF, NCI, or ACS.

Author Contributions:

Conceptualization, YS, JMLE; Methodology, YS, MD, MM, KE, SB, JMLE; Investigation, YS, MD, MM, WH, AD, JMLE; Formal Analysis, YS, MM, MD, JMLE; Visualization, YS, MM, JMLE; Supervision, JMLE; Funding Acquisition, JMLE; Writing – Original Draft, YS, JMLE; Writing – Review and Editing, YS, MD, MM, JMLE.

Declaration of Interests:

None

Methods

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by Lead Contact, John M.L. Ebos (John.Ebos@RoswellPark.org).

Cell lines

Cell used in this study include: Mouse mammary carcinoma EMT6 (from A. Gudkov, Roswell Park Comprehensive Cancer Center, RPCCC), colorectal carcinoma CT26 (A. Gudkov), mouse kidney RENCA (from R. Pili, RPCCC) and melanoma B16 control and PD-L1 knockout cells (from David Escors, Navarrabiomed as described previously¹³). Cells were maintained in RPMI (Corning cellgro #10-040-CV) supplemented with 5% v/v FBS (Corning cellgro; 35-010-CV). All cells were maintained at 37°C with 5% CO₂ in a humidified incubator.

Drug and recombinant protein concentrations

IgG1 (NIP228, AstraZeneca), IgG2a (I-1177, Leinco Technologies Inc), αPD-L1 (clone 80, AstraZeneca), αPD-L1 (MIH5, from M. Azuma, Tokyo Medical and Dental University¹⁰⁵) and anti-IL6 (BE0046/MP5-20F3, BioXCell) were prepared as follows: For *in vivo* experiments: αPD-L1 (Clone80) and anti-IL6 (MP5-20F3) were diluted in PBS and administered by intraperitoneal injection at (250μg/mouse/3days) or (100μg/mouse/3days) respectively. Tumor-related differences between any vehicle or IgG groups were not observed. *In vitro*, IgG (NIP228 or I-1177) and αPD-L1 (clone80 or MIH5) in PBS was directly added to media for maintenance at a concentration of 0.5μg/ml; anti-IL6 was used at a concentration of 10μg/ml; recombinant IFN-

alpha-2 (50525-MNAY, Sino Biological), IFN-beta (50708-MCCH, Sino Biological), IFN γ (315-05, Peprotech) were used at 10ng/ml.

shRNA knockdown studies

For production of IFNAR1 knockdown lentivirus, pLKO.1-puro shRNA plasmid DNA was isolated from bacteria glycerol stocks (TRCN0000301483; Sigma Aldrich) using E.Z.N.A.® Plasmid Mini Kit I (Omega Bio-tek, Inc.). To produce lentiviral media, 293T cells were transiently co-transfected with DNA from the lentiviral pLKO.1-puro shRNA plasmid and psPAX2 and pMD2.G packaging plasmids using LipoD293™ Transfection Reagent (SignaGen Laboratories.) Conditioned media containing virions was harvested after 24 and 48 hours, filtered through a 0.45- μ m membrane, and used to infect EMT6-P and PDR cells. Cells were infected with the shRNA and vector controls by spin inoculation at 600 $\times$ g for 45 min at room temperature in the presence of 5 μ g/ml polybrene. Viruses were removed after an additional 6hr incubation at 37°C/5% CO₂ and cell culture media was replaced. Puromycin selection was then conducted for 2 weeks at 2 μ g/ml until stably infected cells were generated. Knockdown was confirmed via flow cytometry analysis.

Mouse tumor models

Study Approval

Animal tumor model studies were performed in strict accordance with the recommendations in the Guide for Care and Use of Laboratory Animals of the National Institutes of Health and according to guidelines of the IACUC at RPCCC (Protocol: 1227M).

Orthotopic Tumor Implantations

EMT6 (5×10^5 cells in 100 μ l RPMI), RENCA (4×10^4 cells in 5 μ l 1:1 RPMI:Matrigel) were implanted orthotopically into the right inguinal mammary fat pad or left kidney subcapsular space respectively in 6-8 week old female Balb/c mice. Isoflurane (anesthesia) and buprenorphine (analgesic) were used during all surgical implantations. Mammary fat pad tumors were measured using Vernier calipers and volumes were calculated using the formula $(\text{width}^2 \times \text{length}) \times 0.5$. Kidney luciferase expressing tumors were assessed for bioluminescence activity bi-weekly. All animals were assessed 2-3 times daily by veterinary staff or personnel approved by IACUC for pre-defined endpoints. Institutional endpoints included primary tumor-based morbidities ($>2000\text{mm}^3$ volume) and metastasis related morbidities (labored breathing, 20% weight loss, cachexia, limb paralysis). All mice were randomized before implantation.

Resistance cell derivation and maintenance

For *in vivo*-derived PDR cell variants, mice were orthotopically implanted with EMT6 or RENCA and treated with α PD-L1 (Clone80) until institutional endpoint. For both EMT6 and RENCA, parental (P) cell lines were obtained from IgG-treated mice and used as controls. All variants were selected from primary tumors which were minced, enzymatically digested (Miltenyi Biotics; 130-095-929), and then placed in RPMI media (supplemented with 5% v/v FBS, 100IU/ml penicillin and 1000 μ g/ml streptomycin) with IgG (NIP288) for P variants or with α PD-L1 (clone80) (0.5 μ g/ml) for PDR variants. Antibiotics were then removed 1 week after *in vivo* cell selection. For derivation of PDR^{VITRO} cell variants, EMT6 and CT26 cells were treated with α PD-L1 antibodies (clone 80 at 0.5 μ g/ml or MIH5 at 0.5 μ g/ml, respectively) for >4 weeks.

Cell proliferation assay

Proliferation was examined using CellTiter 96 Aqueous Non-Radioactive cell proliferation (MTS) assay (Promega; G1112). For 5 day growth studies, 200 cells/well were plated in 48-well plates. The next day, cells were treated with recombinant IFNs or anti-IL6. Treatments were replaced every 2 days or removed daily for MTS measure of viability. RPMI +5% FBS was mixed with MTS per manufacturer instructions and added to cells at timepoints. After 2 hour incubation, optical density was measured at a wavelength of 490nm (Bio-Rad xMark).

RNA isolation

Cells were plated at 80,000 cells/well in a 6 well plate with corresponding treatments as indicated. 48 hours later, total RNA was isolated using QIAshredder (QIAGEN; 79654) and RNase mini kit (QIAGEN; 74104). Genomic DNA was then digested using DNaseI (QIAGEN; 79254) per manufacturer instructions. RNA concentration was determined using nanodrop 2000c (Thermo Scientific) before RNAseq and PCR analysis.

qRT-PCR

For reverse transcription using iScript cDNA synthesis kit (Bio-rad; 170-8891), 1µg RNA was used according to the manufacturer's instructions. qRT-PCR was performed using iTaq SYBR Green Supermix (Bio-rad; 1725121). Thermocycling parameters were: 10 min at 95°C, 15 sec at 95°C, 40 cycles at 95°C for 15 sec at 95°C and 1 min at 60°C, 1 min at 95°C, followed by a melting curve: 55 to 95°C with increments of 0.5°C for 5 sec. Relative gene expression was calculated using the formula $2^{-[CT(\text{House Keeping Gene}) - Ct(\text{Gene of Interest})]}$, with CT representing the fixed threshold cycle value for fluorescent signal. Gapdh and Actb were used for housekeeping genes. Oligonucleotides were purchased from Integrated DNA Technologies (IDT).

Proteome profiler array

Cells were lysed with lysis buffer 17 (R&D Systems; 895943) supplemented with protease cocktail (Fisher Scientific, PI78430). Total protein levels were quantified with DC protein assay (Bio-Rad; 500-0112). 200µg of total mouse protein samples were analyzed respectively with a Mouse XL Cytokine Array Kit (R&D Systems; ARY028) per manufacturer instructions. Membranes were exposed to X-ray films, which were imaged (digitized) with ChemiDoc System (Bio-Rad) and analyzed with Image Lab Software (Bio-Rad).

ELISA analysis

Cells were lysed with lysis buffer I (20mM Tris (pH7.5), 127mM NaCl, 10% Glycerol, 1% v/v NP40 (Igepal), 100mM NaF, 1mM Na₃VO₄) and protein concentrations were quantified with DC protein assay. For conditioned media collection, cells were counted for normalization. IL-6, phospho-STAT3, and PD-L1 were measured using mouse IL6 ELISA (431304, Biolegend), mouse phospho-STAT3 ELISA (7300C), and mouse PD-L1 DuoSet ELISA (DY1019-05).

Western blot analysis

Cells were lysed with lysis buffer II (50mM Tris (pH8), 2% w/v SDS, 5mM EDTA, 3mM EGTA, 25mM NaF, 1mM Na₃VO₄) supplemented with Halt™ protease inhibitor (Thermo Fischer Scientific 78429). Lysates were sonicated for 2 seconds and total protein concentration was quantified with DC protein assay. Proteins samples were prepared with 1/5 volume of 5x SDS-PAGE sample buffer (250mM Tris pH6.8, 10% w/v SDS, 25% v/v glycerol, 500mM DTT, and bromophenol blue). Proteins (40 µg per lane) were resolved by SDS-PAGE, electrotransferred to

Immobilon-P membrane, and incubated with a primary antibody diluted as recommended by the manufacturer. Membranes were then probed with a horseradish peroxidase-conjugated secondary antibody (Promega W4011 and W4021) and protein signals were developed using the Pierce ECL Western blotting substrate (Thermo Scientific; 32106). X-ray films were imaged (digitized) with ChemiDoc System and analyzed with Image Lab Software. Primary antibodies were purchased from Cell signaling (phospho-STAT1 Tyr701 9167S, STAT1 14994, phospho-STAT3 Tyr705 9145T, STAT3 9139T) and Sigma Aldrich (β -actin, A5441).

Splenocyte Division and Activation Assays

Spleens were harvested from Balb/c mice, mechanically dissociated by passing through a 70 μ m filter, and collected in complete RPMI media (supplemented with 10% heat-inactivated FBS, 1% non-essential amino acids, 1% sodium pyruvate, 1% penicillin/streptomycin, and 0.1% β -mercaptoethanol). Splenocytes were then treated with RBC lysis buffer (Biolegend, 420301) and incubated overnight. The next day, splenocytes were stained with CFSE (Biolegend, 423801), stimulated with anti-mouse CD3 (Biolegend, 100202) and CD28 (Biolegend, 102102) according to manufacturer recommendations. To generate conditioned media, 7 x 10⁶ tumor cells were plated with 10ml of RPMI (supplemented with 5% FBS) in a 10-cm dish. After 72 hours, conditioned media was collected and passed through a 0.2 μ m filter. Splenocytes were then plated in a 1:1 ratio of complete RPMI:conditioned media at 400,000 cells per well in a 96-well plate. After 72 hours of incubation splenocytes were treated for 5 hours with activation cocktail with brefeldin A1 (Biolegend, 423303) before staining for CD45 (Biolegend, 103128), CD8b.2 (Biolegend, 140416), Granzyme B (Biolegend, 515408), IFN γ (Biolegend, 505808), and CD69 (Biolegend, 104514) according to manufacture instructions.

For tumor cell co-culture experiments, 1×10^4 tumor cells were plated in a 24-well plate per well and allowed to adhere overnight. The next day, 1×10^6 stained and stimulated splenocytes were added per well. After 72 hours of incubation, splenocytes were processed as described above and adherent tumor cells were concurrently collected for Annexin V (Biolegend, 640920) and 7-AAD staining (Biolegend, 420404) via flow cytometry according to manufacturer instructions.

Flow cytometry analysis of cell surface proteins

Cells were plated at 80,000 cells/well in a 6 well plate. After two days, cells were collected by accutase (Biolegend, 423201) and analyzed by flow cytometry for H-2Kb/H-2Db (Biolegend, 114613) expression according to manufacture instructions.

Whole transcriptome expression analysis

RNA sequencing for tumor tissue-derived EMT6-PDR, and tumor cell line-derived EMT6-PDR^{VITRO} and RENCA-PDR cells, were performed utilizing the Genomic shared resource at RPCCC as previously described¹⁰⁶. Sequencing library were prepared with TruSeq Stranded mRNA kit (Illumina Inc), from 1 µg total RNA, according to manufacturer's instructions. PolyA selection, RNA purification, fragmentation and priming for cDNA synthesis was performed. Using random primers, fragmented RNA was then reverse transcribed into first-strand cDNA. RNA template was then removed, a replacement strand was synthesized and dUTP was incorporated in place of dTTP to generate ds cDNA. ds cDNA was separated from second-strand reaction mix using AMPure XP beads (Beckman Coulter) resulting in blunt-ended cDNA. One 'A' nucleotide was added to the 3' ends of the blunt fragments. Multiple indexing adapters, containing one 'T' nucleotide on the 3' end of the adapter, were ligated to the ends of the ds cDNA, preparing them

for hybridization onto a flow cell. Adapter ligated libraries were amplified by PCR, purified using Ampure XP beads, and validated for appropriate size on a 4200 TapeStation D1000 Screentape (Agilent Technologies, Inc.). The DNA libraries were quantitated using KAPA Biosystems qPCR kit, and were pooled together in an equimolar fashion, following experimental design criteria. DNA library pool was denatured and diluted to 2.4pM with 1% PhiX control library added. The resulting pool was then loaded into the appropriate NextSeq Reagent cartridge, as determined by the number of sequencing cycles desired, and sequenced on a NextSeq500 following the manufacturer's recommended protocol (Illumina Inc.). Sequencing quality control was assessed using FASTQC v0.11.5 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Reads were aligned to the mouse genome GRCM38 M16 (genocode) using STAR v2.6.0a¹⁰⁷ and post-alignment quality control was assessed using RSeQC v2.6.5¹⁰⁸. Aligned reads were quantified using RSEM v1.3.1¹⁰⁹. Counts from RSEM were then filtered and then upper quartile normalized using R package edgeR. Data from RENCA and EMT6 studies were deposited in GEO (accession number: Pending).

Gene Ontology Analysis/Cytoscape

Differentially expressed genes with products located in extracellular regions were identified using gene ontology databases (GO:00005576) as previously described^{19,110}. GO Biological processes terms were then assessed using ClueGo via Cytoscape v3.7.2 and significantly enriched terms and corresponding Kappa scores were plotted based on p-values.

Gene Set Enrichment Analysis

Gene set enrichment analysis (GSEA) was conducted to assess comparisons for molecular pathways and gene set correlations. A rank list was first generated using log₂(fold change) gene expression data obtained from limma analysis. GSEA-Preranked was then conducted using a gene-set permutation type with 1000 random permutations to obtain normalized enrichment scores (NES) and false discovery rate (FDR) q-values.

Interferome Analysis

Genes of interest were assessed in the Interferome Database (<http://www.interferome.org/interferome/home.jsp>)³⁵ to examine for evidence of regulation by IFN signaling. Parameters interferome type, subtype, treatment concentration, treatment time, *in vivo/in vitro*, species, system, organ, cell, cell line, normal/abnormal were set to “any”, fold-change thresholds were set to 1.5.

Identification of PTIS

A preliminary αPD-L1 Treatment Induced Signature (PTIS) was identified by compiling upregulated and downregulated targets obtained from transcriptomic (RNAseq of PDR tumor tissues). PTIS was then compiled from targets confirmed in two or more transcriptome or proteomic assays of EMT6-PDR tumors (RNAseq, qRT-PCR, Cytokine array, and ELISA).

CIBERSORT/ImmuCC Analysis

Cibersort tissue deconvolution was performed using the ImmuCC signature to obtain absolute score for various cell types^{49,50,111}. From 25 immune cell type signatures, no values were detected

for eosinophil cells, CD4 Memory T cells, Neutrophil cells, and Plasma Cells; and thus, were excluded for quantification and analysis.

Confirmation of PTIS signature enrichment in published datasets

Previously published clinical and preclinical datasets derived from studies after treatment or after acquired resistance to PD-L1 inhibition were obtained from the Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/) or database of Genotypes and Phenotypes (dbGaP, <https://www.ncbi.nlm.nih.gov/gap/>).

Sceneay et al. 2019 (GSE130472): In this study, whole tissue RNA-seq (Illumina NextSeq500 with paired-end 75bp reads) were performed on 4T1 orthotopically implanted mammary tumors in 8-12 week (young; responsive) or >12months (old, nonresponsive) Balb/c mice treated with α PD-L1 (clone 10F.9G2) or isotype (Clone LTF-2). Tumors were collected when caliper volumes were no larger than $\sim 150\text{mm}^3$ after 3 doses of antibody treatment.

Lan et al. 2018 (GSE107801): In this study, whole tissue RNAseq was (Illumina Hiseq 2500) conducted on EMT6 orthotopically implanted mammary tumors in Balb/c mice treated with α PD-L1 or isotype control. Tumors were collected 6 days after 3 doses of treatment given daily starting 20 days after implantation.

Efremova et al. 2018 (GSE93017): In this study, whole tissue RNAseq (Ion Torrent Proton) was conducted on MC38 subcutaneously implanted tumors in C57Bl/6 mice treated with α PD-L1 (Clone 10F.9G2) or isotype (Clone LTF-2) every 3-4 days until day 14 after implantation.

Gettinger et al. 2018 (phs001464.v1.p1): In this study, pre-treatment and post-treatment/acquired resistant biopsies were obtained from patients receiving various immune checkpoint inhibitor treatments (PD-L1, PD-1, CTLA-4 targeted therapies) for RNA-seq analysis

(Illumina HiSeq2500) from formalin fix paraffin embedded samples. For validation analysis, all pretreatment samples were compared to samples after acquired resistance to PD-L1 inhibition.

Note: the name of the PD-L1 inhibitor was not provided in this publication.

Paulson et al. 2018 (GSE117988, GSE118056): In this study, single cell RNAseq analysis on tumor tissues were conducted on an untreated patient biopsy (Illumina HiSeq 2500) and a patient biopsy at acquired resistance (unmatched) after α PD-L1 (avelumab), MCPyV-specific T cells, and radiation (Illumina NovaSeq 6000). Processed data were obtained from the GEO database. R packages SingleCellExperiment¹¹², scater¹¹³, limma¹¹⁴, and Rtsne were used for analysis. Counts were quartile normalized and converted to counts per million (CPM). Clustered enrichment analysis was then conducted using markers PTRC/CD45 (tumor cells), CD3D (T cells), and CD68 (Macrophages) similar to previously described⁴⁵.

PTIS signature expression levels in these datasets were compared by average counts per million (CPM) levels or GSEA enrichment (defined by $FDR \leq 0.25$).

Statistical analysis

Analysis was conducted using the GraphPad Prism software package v8.4.0 (GraphPad software Inc., San Diego, CA) and R v3.6.0 through RStudio v1.1.463(Integrated Development for R; RStudio, Inc., Boston, MA URL <http://www.rstudio.com/>). For *in vivo* studies, results are represented as mean $\pm$ standard deviation (SD) or standard error of mean (SEM), as indicated. Kaplan-Meier methods were utilized for analysis of percent to institutional endpoint curves. Fold change differences between treatment control groups were assessed via two-way ANOVA. For all results, comparisons between two groups were made with Student's two-tailed unpaired t-test, whereas one-way ANOVA was used for comparison of more than two groups. Tumor volume and

bioluminescence measurements were compared for specified time points. A minimum FDR value of 0.25 was use for GSEA analysis (as indicated as described by the user guide) and significance level of 0.05 was used for all other analyses.

References

- 1 Kerbel, R. S. & Ebos, J. M. Peering into the aftermath: The inhospitable host? *Nat.Med.* **16**, 1084-1085 (2010).
- 2 Ebos, J. M. Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis. *Cancer Res* **75**, 3427-3435, doi:10.1158/0008-5472.CAN-15-0308 (2015).
- 3 Madden, E. C., Gorman, A. M., Logue, S. E. & Samali, A. Tumour Cell Secretome in Chemoresistance and Tumour Recurrence. *Trends in cancer* **6**, 489-505, doi:10.1016/j.trecan.2020.02.020 (2020).
- 4 Tsukamoto, H. *et al.* Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. *Cancer research* **78**, 5011-5022, doi:10.1158/0008-5472.CAN-18-0118 (2018).
- 5 Sanmamed, M. F. *et al.* Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. *Ann Oncol* **28**, 1988-1995, doi:10.1093/annonc/mdx190 (2017).
- 6 Naqash, A. R., Yang, L. V., Sanderlin, E. J., Atwell, D. C. & Walker, P. R. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. *Acta Oncol* **57**, 705-708, doi:10.1080/0284186X.2017.1406668 (2018).
- 7 Bridge, J. A., Lee, J. C., Daud, A., Wells, J. W. & Bluestone, J. A. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. *Front Med (Lausanne)* **5**, 351, doi:10.3389/fmed.2018.00351 (2018).
- 8 Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. *Cancer Discov* **8**, 1069-1086, doi:10.1158/2159-8290.CD-18-0367 (2018).
- 9 Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. *Science* **359**, 1350-1355, doi:10.1126/science.aar4060 (2018).
- 10 Chang, C. H. *et al.* Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. *Cell* **162**, 1229-1241, doi:10.1016/j.cell.2015.08.016 (2015).
- 11 Clark, C. A. *et al.* Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. *Cancer Res* **76**, 6964-6974, doi:10.1158/0008-5472.CAN-16-0258 (2016).
- 12 Wu, X. *et al.* Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. *Heliyon* **4**, e01039, doi:10.1016/j.heliyon.2018.e01039 (2018).
- 13 Gato-Canas, M. *et al.* PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. *Cell Rep* **20**, 1818-1829, doi:10.1016/j.celrep.2017.07.075 (2017).
- 14 Wang, S. *et al.* Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta4/SNAI1/SIRT3 signaling pathway. *Oncogene* **37**, 4164-4180, doi:10.1038/s41388-018-0252-x (2018).
- 15 Du, W. *et al.* KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway. *Cell Death Differ* **28**, 1284-1300, doi:10.1038/s41418-020-00651-5 (2021).

- 16 Feng, D. *et al.* BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. *Oncogene* **38**, 6752-6766, doi:10.1038/s41388-019-0919-y (2019).
- 17 Azuma, T. *et al.* B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. *Blood* **111**, 3635-3643, doi:10.1182/blood-2007-11-123141 (2008).
- 18 Escors, D. *et al.* The intracellular signalosome of PD-L1 in cancer cells. *Signal Transduct Target Ther* **3**, 26, doi:10.1038/s41392-018-0022-9 (2018).
- 19 Mastri, M. *et al.* Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. *Mol Cancer Ther* **17**, 1602-1612, doi:10.1158/1535-7163.MCT-17-1066 (2018).
- 20 Benci, J. L. *et al.* Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. *Cell* **167**, 1540-1554 e1512, doi:10.1016/j.cell.2016.11.022 (2016).
- 21 Benci, J. L. *et al.* Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. *Cell* **178**, 933-948 e914, doi:10.1016/j.cell.2019.07.019 (2019).
- 22 Vraetz, T. *et al.* Regulation of beta2-microglobulin expression in different human cell lines by proinflammatory cytokines. *Nephrol Dial Transplant* **14**, 2137-2143, doi:10.1093/ndt/14.9.2137 (1999).
- 23 Sade-Feldman, M. *et al.* Resistance to checkpoint blockade therapy through inactivation of antigen presentation. *Nat Commun* **8**, 1136, doi:10.1038/s41467-017-01062-w (2017).
- 24 Garcia-Diaz, A. *et al.* Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. *Cell reports* **19**, 1189-1201, doi:10.1016/j.celrep.2017.04.031 (2017).
- 25 Jacquelot, N. *et al.* Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. *Cell Res*, doi:10.1038/s41422-019-0224-x (2019).
- 26 Chen, J. *et al.* Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation. *J Clin Invest* **129**, 4224-4238, doi:10.1172/JCI127458 (2019).
- 27 Chen, L. *et al.* CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. *Cancer Discov* **8**, 1156-1175, doi:10.1158/2159-8290.CD-17-1033 (2018).
- 28 Boukhaled, G. M., Harding, S. & Brooks, D. G. Opposing Roles of Type I Interferons in Cancer Immunity. *Annu Rev Pathol* **16**, 167-198, doi:10.1146/annurev-pathol-031920-093932 (2021).
- 29 Cheon, H., Borden, E. C. & Stark, G. R. Interferons and their stimulated genes in the tumor microenvironment. *Seminars in oncology* **41**, 156-173, doi:10.1053/j.seminoncol.2014.02.002 (2014).
- 30 Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. *Nature reviews. Cancer* **16**, 131-144, doi:10.1038/nrc.2016.14 (2016).
- 31 Lan, Y. *et al.* Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. *Sci Transl Med* **10**, doi:10.1126/scitranslmed.aan5488 (2018).

- 32 Clift, R., Souratha, J., Garrovillo, S. A., Zimmerman, S. & Blouw, B. Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy. *Cancer research* **79**, 4149-4159, doi:10.1158/0008-5472.CAN-18-3060 (2019).
- 33 Schofield, D. J. *et al.* Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. *MAbs* **13**, 1857100, doi:10.1080/19420862.2020.1857100 (2021).
- 34 Snell, L. M., McGaha, T. L. & Brooks, D. G. Type I Interferon in Chronic Virus Infection and Cancer. *Trends Immunol* **38**, 542-557, doi:10.1016/j.it.2017.05.005 (2017).
- 35 Rusinova, I. *et al.* Interferome v2.0: an updated database of annotated interferon-regulated genes. *Nucleic Acids Res* **41**, D1040-1046, doi:10.1093/nar/gks1215 (2013).
- 36 Mosely, S. I. *et al.* Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. *Cancer immunology research* **5**, 29-41, doi:10.1158/2326-6066.CIR-16-0114 (2017).
- 37 Liu, H. *et al.* Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. *Nat Med* **25**, 95-102, doi:10.1038/s41591-018-0302-5 (2019).
- 38 Weichselbaum, R. R. *et al.* An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. *Proc Natl Acad Sci U S A* **105**, 18490-18495, doi:10.1073/pnas.0809242105 (2008).
- 39 Thorsson, V. *et al.* The Immune Landscape of Cancer. *Immunity* **48**, 812-830 e814, doi:10.1016/j.immuni.2018.03.023 (2018).
- 40 Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* **1**, 417-425, doi:10.1016/j.cels.2015.12.004 (2015).
- 41 Higgs, B. W. *et al.* Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab. *Clinical cancer research : an official journal of the American Association for Cancer Research* **24**, 3857-3866, doi:10.1158/1078-0432.CCR-17-3451 (2018).
- 42 Sceneay, J. *et al.* Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. *Cancer Discov* **9**, 1208-1227, doi:10.1158/2159-8290.CD-18-1454 (2019).
- 43 Efremova, M. *et al.* Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. *Nat Commun* **9**, 32, doi:10.1038/s41467-017-02424-0 (2018).
- 44 Gettinger, S. *et al.* Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. *Cancer Discov* **7**, 1420-1435, doi:10.1158/2159-8290.CD-17-0593 (2017).
- 45 Paulson, K. G. *et al.* Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. *Nat Commun* **9**, 3868, doi:10.1038/s41467-018-06300-3 (2018).
- 46 Schoggins, J. W. Interferon-Stimulated Genes: What Do They All Do? *Annu Rev Virol* **6**, 567-584, doi:10.1146/annurev-virology-092818-015756 (2019).

- 47 Bekisz, J., Baron, S., Balinsky, C., Morrow, A. & Zoon, K. C. Antiproliferative Properties of Type I and Type II Interferon. *Pharmaceuticals (Basel)* **3**, 994-1015, doi:10.3390/ph3040994 (2010).
- 48 Garcia-Diaz, A. *et al.* Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. *Cell reports* **29**, 3766, doi:10.1016/j.celrep.2019.11.113 (2019).
- 49 Chen, Z. *et al.* Inference of immune cell composition on the expression profiles of mouse tissue. *Sci Rep* **7**, 40508, doi:10.1038/srep40508 (2017).
- 50 Chen, Z. *et al.* seq-ImmuCC: Cell-Centric View of Tissue Transcriptome Measuring Cellular Compositions of Immune Microenvironment From Mouse RNA-Seq Data. *Front Immunol* **9**, 1286, doi:10.3389/fimmu.2018.01286 (2018).
- 51 Smahel, M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. *Int J Mol Sci* **18**, doi:10.3390/ijms18061331 (2017).
- 52 Medema, J. P. *et al.* Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. *Proc Natl Acad Sci U S A* **98**, 11515-11520, doi:10.1073/pnas.201398198 (2001).
- 53 Bhat, P., Leggatt, G., Waterhouse, N. & Frazer, I. H. Interferon-gamma derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. *Cell Death Dis* **8**, e2836, doi:10.1038/cddis.2017.67 (2017).
- 54 Lindsey, W. B. *et al.* CD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recovery. *Cytotherapy* **9**, 123-132, doi:10.1080/14653240601182838 (2007).
- 55 Johnson, D. E., O'Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nat Rev Clin Oncol* **15**, 234-248, doi:10.1038/nrclinonc.2018.8 (2018).
- 56 Lu, C. *et al.* Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. *Journal for immunotherapy of cancer* **7**, 157, doi:10.1186/s40425-019-0635-8 (2019).
- 57 Katlinski, K. V. *et al.* Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. *Cancer Cell* **31**, 194-207, doi:10.1016/j.ccell.2017.01.004 (2017).
- 58 Schoenfeld, A. J. & Hellmann, M. D. Acquired Resistance to Immune Checkpoint Inhibitors. *Cancer cell* **37**, 443-455, doi:10.1016/j.ccell.2020.03.017 (2020).
- 59 Shah, S. *et al.* Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. *Oncotarget* **9**, 4375-4384, doi:10.18632/oncotarget.23315 (2018).
- 60 Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. *Cell* **168**, 707-723, doi:10.1016/j.cell.2017.01.017 (2017).
- 61 Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. *Nature reviews. Immunology* **20**, 25-39, doi:10.1038/s41577-019-0218-4 (2020).
- 62 Chocarro de Erauso, L. *et al.* Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? *Front Pharmacol* **11**, 441, doi:10.3389/fphar.2020.00441 (2020).

- 63 Gubin, M. M. *et al.* Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. *Nature* **515**, 577-581, doi:10.1038/nature13988 (2014).
- 64 Wei, S. C. *et al.* Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. *Cell* **170**, 1120-1133 e1117, doi:10.1016/j.cell.2017.07.024 (2017).
- 65 Gubin, M. M. *et al.* High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. *Cell* **175**, 1014-1030 e1019, doi:10.1016/j.cell.2018.09.030 (2018).
- 66 Ghebeh, H. *et al.* Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. *Breast cancer research : BCR* **12**, R48, doi:10.1186/bcr2605 (2010).
- 67 Gupta, H. B. *et al.* Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. *Signal Transduct Target Ther* **1**, 16030, doi:10.1038/sigtrans.2016.30 (2016).
- 68 Al Zaid Siddiquee, K. & Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. *Cell Res* **18**, 254-267, doi:10.1038/cr.2008.18 (2008).
- 69 Jiang, L. *et al.* Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. *Cell* **183**, 1219-1233 e1218, doi:10.1016/j.cell.2020.10.045 (2020).
- 70 Lee, H. T. *et al.* Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. *Sci Rep* **7**, 5532, doi:10.1038/s41598-017-06002-8 (2017).
- 71 von Pawel, J. *et al.* Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. *European journal of cancer* **107**, 124-132, doi:10.1016/j.ejca.2018.11.020 (2019).
- 72 Jansen, Y. J. L. *et al.* Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. *Ann Oncol* **30**, 1154-1161, doi:10.1093/annonc/mdz110 (2019).
- 73 Pokorny, R. *et al.* (American Society of Clinical Oncology, 2020).
- 74 Marron, T. U. *et al.* Considerations for treatment duration in responders to immune checkpoint inhibitors. *Journal for immunotherapy of cancer* **9**, doi:10.1136/jitc-2020-001901 (2021).
- 75 Danson, S. *et al.* Are we over-treating with checkpoint inhibitors? *British journal of cancer* **121**, 629-630, doi:10.1038/s41416-019-0570-y (2019).
- 76 Chen, P. L. *et al.* Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. *Cancer Discov* **6**, 827-837, doi:10.1158/2159-8290.CD-15-1545 (2016).
- 77 Yamazaki, N. *et al.* Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. *Cancer Sci* **108**, 1022-1031, doi:10.1111/cas.13226 (2017).
- 78 Murakami, N., Borges, T. J., Yamashita, M. & Riella, L. V. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. *Clin Kidney J* **9**, 411-417, doi:10.1093/ckj/sfw024 (2016).

- 79 Okiyama, N. & Tanaka, R. Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6. *Nihon Rinsho Meneki Gakkai Kaishi* **40**, 95-101, doi:10.2177/jsci.40.95 (2017).
- 80 Nixon, A. B. *et al.* Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? *Journal for immunotherapy of cancer* **7**, 325, doi:10.1186/s40425-019-0799-2 (2019).
- 81 Keegan, A. *et al.* Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. *Journal for immunotherapy of cancer* **8**, doi:10.1136/jitc-2020-000678 (2020).
- 82 Slaney, C. Y., Kershaw, M. H. & Darcy, P. K. Trafficking of T cells into tumors. *Cancer research* **74**, 7168-7174, doi:10.1158/0008-5472.CAN-14-2458 (2014).
- 83 Mikucki, M. E. *et al.* Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. *Nat Commun* **6**, 7458, doi:10.1038/ncomms8458 (2015).
- 84 Qu, Y. *et al.* Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment. *Cell reports* **32**, 108115, doi:10.1016/j.celrep.2020.108115 (2020).
- 85 Lunardi, S., Lim, S. Y., Muschel, R. J. & Brunner, T. B. IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. *Oncoimmunology* **4**, e1027473, doi:10.1080/2162402X.2015.1027473 (2015).
- 86 Li, C. X. *et al.* CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. *J Hepatol* **65**, 944-952, doi:10.1016/j.jhep.2016.05.032 (2016).
- 87 Wang, Z. *et al.* Peyer's patches-derived CD11b(+) B cells recruit regulatory T cells through CXCL9 in dextran sulphate sodium-induced colitis. *Immunology* **155**, 356-366, doi:10.1111/imm.12977 (2018).
- 88 Ramos-Casals, M. *et al.* Immune-related adverse events of checkpoint inhibitors. *Nat Rev Dis Primers* **6**, 38, doi:10.1038/s41572-020-0160-6 (2020).
- 89 Rotz, S. J. *et al.* Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. *Pediatr Blood Cancer* **64**, doi:10.1002/pbc.26642 (2017).
- 90 Ceschi, A., Nosedà, R., Palin, K. & Verhamme, K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. *Front Pharmacol* **11**, 557, doi:10.3389/fphar.2020.00557 (2020).
- 91 Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D. & Haribabu, B. Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors. *J Immunol* **197**, 2016-2026, doi:10.4049/jimmunol.1502376 (2016).
- 92 Zaretsky, J. M. *et al.* Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. *N Engl J Med* **375**, 819-829, doi:10.1056/NEJMoa1604958 (2016).
- 93 Manguso, R. T. *et al.* In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. *Nature* **547**, 413-418, doi:10.1038/nature23270 (2017).
- 94 Torrejon, D. Y. *et al.* Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. *Cancer Discov* **10**, 1140-1157, doi:10.1158/2159-8290.CD-19-1409 (2020).

- 95 Pai, C. S. *et al.* Clonal Deletion of Tumor-Specific T Cells by Interferon-gamma Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. *Immunity* **50**, 477-492 e478, doi:10.1016/j.immuni.2019.01.006 (2019).
- 96 Lederle, W. *et al.* IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. *International journal of cancer* **128**, 2803-2814, doi:10.1002/ijc.25621 (2011).
- 97 Kitamura, H. *et al.* IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. *Immunity* **23**, 491-502, doi:10.1016/j.immuni.2005.09.010 (2005).
- 98 Fu, X. L. *et al.* Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression. *Cancer immunology, immunotherapy : CII* **66**, 1597-1608, doi:10.1007/s00262-017-2052-5 (2017).
- 99 Tsukamoto, H., Senju, S., Matsumura, K., Swain, S. L. & Nishimura, Y. IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. *Nat Commun* **6**, 6702, doi:10.1038/ncomms7702 (2015).
- 100 Tsukamoto, H. *et al.* Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity. *Cancer Sci* **109**, 523-530, doi:10.1111/cas.13433 (2018).
- 101 Stroud, C. R. *et al.* Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. *J Oncol Pharm Pract* **25**, 551-557, doi:10.1177/1078155217745144 (2019).
- 102 Doms, J., Prior, J. O., Peters, S. & Obeid, M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. *Ann Oncol* **31**, 1273-1275, doi:10.1016/j.annonc.2020.05.005 (2020).
- 103 Flores-Toro, J. A. *et al.* CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. *Proc Natl Acad Sci U S A* **117**, 1129-1138, doi:10.1073/pnas.1910856117 (2020).
- 104 Wang, X. *et al.* PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. *Signal Transduct Target Ther* **5**, 38, doi:10.1038/s41392-020-0144-8 (2020).
- 105 Tsushima, F. *et al.* Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. *Eur J Immunol* **33**, 2773-2782, doi:10.1002/eji.200324084 (2003).
- 106 Dolan, M. *et al.* Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. *PloS one* **14**, e0220101, doi:10.1371/journal.pone.0220101 (2019).
- 107 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21, doi:10.1093/bioinformatics/bts635 (2013).
- 108 Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. *Bioinformatics* **28**, 2184-2185, doi:10.1093/bioinformatics/bts356 (2012).
- 109 Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323, doi:10.1186/1471-2105-12-323 (2011).

- 110 Mastri, M. *et al.* A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal. *Cell reports* **25**, 3706-3720 e3708, doi:10.1016/j.celrep.2018.12.017 (2018).
- 111 Newman, A. M. *et al.* Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* **12**, 453-457, doi:10.1038/nmeth.3337 (2015).
- 112 Amezquita, R. A. *et al.* Orchestrating single-cell analysis with Bioconductor. *Nat Methods* **17**, 137-145, doi:10.1038/s41592-019-0654-x (2020).
- 113 McCarthy, D. J., Campbell, K. R., Lun, A. T. & Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. *Bioinformatics* **33**, 1179-1186, doi:10.1093/bioinformatics/btw777 (2017).
- 114 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007 (2015).

Figure 1 Acquired resistance anti-PD-L1 drug resistance (PDR) increases secretory profiles enriched for type I IFN regulated genes

- (a)** Schematic showing orthotopic breast EMT6 model of acquired resistance to α PD-L1 inhibition
- (b)** Continuous α PD-L1 treatment in Balb/c mice (n=3-4) bearing orthotopically-implanted mouse mammary EMT6 cells (left) and the time taken to reach endpoint defined by primary tumor size (2000mm³) and animal morbidity.
- (c-f)** RNA sequencing analysis of EMT6-P and EMT6-PDR tumor tissues.
- (c)** Differentially expressed genes (Log_2 [Fold Change] ≤ -2 or ≥ 2) in EMT6-PDR as summarized by dot plot (left) and heatmap (right). Red = upregulated; blue = downregulated.
- (d)** Summary of stroma/tumor microenvironment, growth factor signaling, and cytokine signaling gene sets with significant positive enrichment found in PDR tumors via GSEA of all canonical pathways (C2, Molecular Signatures Database Collection).
- (e)** Cytoscape GO analysis of significantly enriched biological processes in upregulated secretory genes, grouped by signaling categories. Size of circles correspond to FDR significance of each process and lines represent term-term interactions defined by Kappa score.
- (f)** Bar graph representing Interferome Database secretory genes up- and down-regulated in EMT6-PDR (compared to EMT6-P).
- (g)** Type I IFNs and additional ISGs in EMT6-PDR selected cell variants (qRT-PCR). † represent genes associated with secretory proteins.
- (h)** Schematic showing orthotopic kidney RENCA tumor model of innate resistance to α PD-L1 inhibition (left) and BLI of selected tumor variants on day of endpoint (right).
- (i)** BLI quantification of murine RENCA orthotopic tumor growth (left) and kidney weight at endpoint (right) with continuous α PD-L1 treatment (Balb/c mice; n =3).
- (j-k)** GSEA of EMT6-PDR and RENCA-PDR tumor cells (compared to P controls) showing heatmaps representing **(j)** NES of published/Hallmark IFN gene sets, and **(k)**, NES of an IFN-specific gene-set identified in α PD-L1-treated (durvalumab) NSCLC patients (described in Ref 41). (–) indicates expression below detectable thresholds. See Table S1 for details.

*Parental (P); α PD-L1 Drug Resistant (PDR); Gene Set Enrichment Analysis (GSEA); Gene Ontology (GO); interferon stimulated genes (ISGs); Counts per million (CPM); Bioluminescence (BLI); normalized enrichment scores (NES); Non-small cell lung carcinoma (NSCLC). α PD-L1 (clone 80) and IgG were administered at 250 μ g/mouse every 3 days until endpoint. Primary tumor burden was assessed by caliper measurement. Time to institutional endpoint was assessed by Kaplan-Meier. PDR cell variant tumor growth shown as dotted line and time of tumor selection shown with circle for 1B and 1I. Selected EMT6-PDR and EMT6-P variants were maintained in vitro with respective α PD-L1 or IgG antibody (see Methods for details). Quantitative data shown as mean $\pm$ SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$*

Figure 2

Figure 2: An upregulated PTIS signature is enriched in clinical and preclinical models sensitive to α PD-L1 treatment

(a) Generation of an α PD-L1 treatment-induced secretome (PTIS) comprised 13 upregulated gene identified from transcriptome and proteomic analysis using EMT6-PDR cells.

(b-e) PTIS expression in published bulk and single cell RNAseq datasets involving α PD-L1 treatment in preclinical and clinical studies. RENCA-PDR model from this study included.

(b-c) Preclinical studies: PTIS expression using average CPM expression and GSEA in datasets taken from tumor models involving α PD-L1 treatment and found to be **b)** treatment-*sensitive* (GEO: GSE130472, GSE93017, GSE107801) or **c)** treatment-*insensitive* (GEO: GSE130472; RENCA-PDR). Data is compared to vehicle/IgG-treated controls.

(d-e) Clinical studies: PTIS expression using average CPM expression and GSEA in datasets taken from tumor biopsies of α PD-L1 treatment-sensitive patients.

d) NSCLC patients (dbGAP # phs001464.v1.p1): bulk RNAseq from Pre-Tx and Post-Tx tumor sample comparisons (Gray lines indicate matched Pre- and Post-tx samples).

e) MCC patients (GEO: GSE118056): single-cell RNAseq from untreated (No-Tx) or treated (avelumab) tumor samples with Tsne plots (left) representing average $\log_2$ CPM expression of PTIS in whole dataset, and bar graphs (right) representing clustered enrichment analysis populations identified by markers for tumors (CD45-), macrophages (CD68+), and T cells (CD3D+). Tumor sample that received No-Tx was compared to treated.

*α PD-L1 Treatment-Induced Secretome (PTIS); α PD-L1 Drug Resistant (PDR); Counts per million (CPM); Gene set enrichment analysis (GSEA); False Discovery Rate (FDR); Gene Expression Omnibus (GEO); GEO Series records (GSE); database of Genotypes and Phenotypes (dbGaP); t-distributed stochastic neighbor embedding (tsne); Treatment (Tx); non-small cell lung carcinoma (NSCLC); merkel cell carcinoma (MCC) Significance represented as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. Bolded numbers for GSEA represent $FDR < 0.25$ (see Methods).*

Figure 3

Figure 3: Type I IFN stimulation enhances PTIS after acquired PD-L1 resistance

- (a)** ISGs after stimulation with type I/II IFNs in EMT6-PDR cells shown as relative to untreated P controls and represented as bar graphs (qRT-PCR).
- (b)** heatmap summary of results in (a).
- (c)** Secreted IL6 levels in EMT6-P and -PDR tumor cell CM after IFN γ , α , and β stimulation (ELISA).
- (d)** IFNAR1 expression in EMT6-P and -PDR before and after knockdown of IFNAR1 and respective vector controls (Flow).
- (e)** IL6 expression in lysates of EMT6-P and -PDR before and after knockdown of IFNAR1^{KD}, and after IFN β stimulation (ELISA).
- (f)** PD-L1 expression in lysates of EMT6-P and -PDR before and after knockdown of IFNAR1^{KD}, and after IFN β stimulation (ELISA).
- (g)** Phosphorylated and total levels of STAT1/3 in lysates of EMT6-P and -PDR before and after knockdown of IFNAR1^{KD} following IFN β stimulation (Western Blot).
- (h-i)** Densitometry quantification of western blots shown in (G) representing **(H)** total STAT1/3 levels compared to b-actin, and **(I)** relative phosphorylated STAT1/3 levels compared to total STAT1/3 levels.
- (j)** pSTAT3 expression in lysates of EMT6-P and -PDR before and after knockdown of IFNAR1^{KD}, and after IFN β stimulation (ELISA). (ELISA).

*Parental (P); PD-L1 Drug Resistant (PDR); Conditioned Media (CM); Mean Fluorescent Intensity (MFI); IFN stimulated genes (ISGs); IFNAR1 knockdown (IFNAR1^{KD}) shRNA vector control (Cont); Cells were treated with 10ng/ml of IFNs and collected after 15mins (pSTAT3 shown in G), 48 hours (gene expression shown in A-B), and 5 days (proteins shown in C-F). * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$ indicate significance compared untreated controls unless otherwise shown (lines).*

Figure 4

Figure 4: Persistent PD-L1 blockade *in vitro* sensitizes tumor cells to Type I IFN stimulation of PTIS

- (a)** Schematic showing generation of PDR^{VITRO} cell variants following αPD-L1 treatment *in vitro* for >4 weeks.
- (b-e)** RNA sequencing analysis of EMT6-P^{VITRO} and -PDR^{VITRO} (αPD-L1: Clone80) cell variants.
- (b)** Differentially expressed genes ($\log_2$ [Fold Change] ≤ -2 or ≥ 2) in EMT6-PDR^{VITRO} as summarized by dot plot (left) and heatmap (right). Red = upregulated; blue = downregulated.
- (c)** Bar graph summarizing upregulated (red) and downregulated (blue) genes from *in vivo*-derived EMT6 PDR (versus P) and *in vitro*-derived EMT6-PDR^{VITRO} (versus P^{VITRO})
- (d)** Average CPM expression and GSEA of PTIS in EMT6 PDR^{VITRO} dataset.
- (e-f)** GSEA of EMT6-PDR^{VITRO} (compared to P^{VITRO} controls) showing heatmaps representing **(E)** NES of published/Hallmark IFN gene sets, and **(F)**, NES of an IFN-specific gene-set identified in αPD-L1-treated (durvalumab) NSCLC patients (described in Ref 41). (–) indicates expression below detectable thresholds. See Table S1 for details.
- (g)** ISGs after stimulation with type I IFNs in EMT6-PDR^{VITRO} cells shown as relative to untreated controls for each variant and represented as bar graphs (qRTPCR).
- (h)** heatmap summary of results in (g).
- (i)** IL6 expression in CM of CT26-PDR^{VITRO} (αPD-L1: MIH5) and P control cell variants after IFNβ stimulation (ELISA).
- (j)** ISGs after stimulation with IFNβ in B16^{PDL1-KO} cells shown as relative to untreated controls for each variant and represented as bar graphs (qRTPCR). # indicating genes with low levels of expression where increased cDNA input was required for reaction.
- (k)** heatmap summary of results in (j).
- (l)** IL6 expression after IFNβ stimulation in CM of EMT6-PDR^{VITRO} and P control cell variants derived after 1 or >4 weeks of αPD-L1 (clone 80) treatment (ELISA).

*Parental (P); PD-L1 Drug Resistant (PDR); in vitro derived Parental (P^{VITRO}); in vitro derived PD-L1 Drug Resistant (PDR^{VITRO}); Gene Set Enrichment Analysis (GSEA); αPD-L1 Treatment-Induced Secretome (PTIS); interferon stimulated genes (ISGs); normalized enrichment scores (NES); false discovery rate (FDR); Conditioned media (CM); not significant (NS); PD-L1 knockout (PDL1-KO); complementary DNA (cDNA). Cells were treated with 10ng/ml of IFNs and collected after 48 hours for gene expression quantification and after 5 days for IL6 protein expression quantifications. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ except for GSEA where bolded numbers and (*) indicate $FDR < 0.25$*

Figure 5

Figure 5: PDR-mediated immune-protection is IFN signaling-dependent.

- (a)** Cibersort tissue deconvolution analysis of EMT6-P and -PDR RNAseq data using ImmuCC mouse signature with box-plot representing absolute total immune score.
- (b)** Heatmap representing log2 fold change of absolute scores of various immune signatures of results from (A).
- (c)** MHC-I H-2Kd expression in EMT6-P and -PDR cells before and after IFNAR1 knockdown shown as a histogram (top), barplot of P/PDR (bottom left), and log2-fold change comparison of EMT6-P and –PDR-IFNAR1^{KD} variants relative to respective vector controls (bottom right) (flow).
- (d)** Schematic of Balb/c–derived splenocyte proliferation and activation following incubation EMT6-P and –PDR CM for experiments in e-h.
- (e-f)** CD8+ splenocyte division (CSFE dilution) after co-incubation with **(e)** EMT6-P and –PDR variant CM and **(F)** EMT6-P and –PDR-IFNAR1^{KD} variant CM compared to controls (Flow).
- (g-h)** CD8+ splenocyte activation markers expression (Granzyme B, IFN γ , CD69) after co-incubation with **(G)** EMT6-P and –PDR variants and **(h)** EMT6-P and –PDR-IFNAR1^{KD} variant compared to controls (Flow).
- (i)** Schematic of EMT6-P and –PDR tumor cell cytotoxicity following co-culture with Balb/c-derived splenocytes for experiments in J-L (Flow).
- (j-l)** Apoptosis (Annexin V) and cell death (7-AAD) staining of CD45- gated tumor cells after co-incubation with splenocytes showing **(j)** representative contour plots of stimulated splenocyte groups, **(k)** EMT6-P and –PDR variants, and **(l)** EMT6-P and –PDR-IFNAR1^{KD} variants compared to controls (Flow).

*Parental (P); PD-L1 Drug Resistant (PDR); IFNAR1 knockdown (IFNAR1^{KD}); Conditioned Media (CM) * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ compared to vector controls unless noted otherwise. For C, F, H, and L white bars represent vector controls*

Figure 6

Figure 6: Inhibition of PTIS regulators selectively inhibits PDR tumor growth

- (a)** Orthotopic tumor growth and response to anti-IL6 upon re-implantation of EMT6-P and -PDR cell variants (left; n=8; Balb/c) with summary of AUC analysis (left-inset). Log₂ Fold Change analysis comparing anti-IL6 to vehicle controls (right).
- (b)** Orthotopic tumor growth upon re-implantation of EMT6-P and -PDR -IFNAR1^{KD} and respective Cont cell variants (left; n=5-8; Balb/c) with summary of AUC analysis (left-inset). Log₂ Fold Change analysis comparing IFNAR1^{KD} to respective controls (right).
- (c)** AUC analysis for Log₂ Fold Change of treatment or knockdown compared to vehicle or Cont, respectively, for experiments shown in a-b.
- (d)** Metastasis and invasion of mice bearing EMT6-P and -PDR tumors (shown in a-b) with invasion in the peritoneum wall after PBS, anti-IL6, Cont, or IFNAR1^{KD} (n=5-8)
- (e)** Proposed model of IFN-signaling 'rewired' tumor cells following acquired resistance to PD-L1 inhibition

Parental (P); PD-L1 Drug Resistant (PDR); IFNAR1 knockdown (IFNAR1^{KD}); shRNA Vector Control (Cont); Area under the curve (AUC). Anti-IL6 was administered at 100µg/mouse/3 days continuously. Primary tumor burden was assessed by caliper measurement. Quantitative data shown as mean ± SEM.